Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jan 7;110(1):55-62.
doi: 10.1038/bjc.2013.721. Epub 2013 Nov 21.

First-line Gefitinib in Caucasian EGFR Mutation-Positive NSCLC Patients: A phase-IV, Open-Label, Single-Arm Study

Affiliations
Free PMC article
Clinical Trial

First-line Gefitinib in Caucasian EGFR Mutation-Positive NSCLC Patients: A phase-IV, Open-Label, Single-Arm Study

J-Y Douillard et al. Br J Cancer. .
Free PMC article

Abstract

Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).

Treatment: gefitinib 250 mg day(-1) until progression. Primary endpoint: objective response rate (ORR). Secondary endpoints: disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety/tolerability. Pre-planned exploratory objective: EGFR mutation analysis in matched tumour and plasma samples.

Results: Of 1060 screened patients with NSCLC (859 known mutation status; 118 positive, mutation frequency 14%), 106 with EGFR sensitising mutations were enrolled (female 70.8%; adenocarcinoma 97.2%; never-smoker 64.2%). At data cutoff: ORR 69.8% (95% confidence interval (CI) 60.5-77.7), DCR 90.6% (95% CI 83.5-94.8), median PFS 9.7 months (95% CI 8.5-11.0), median OS 19.2 months (95% CI 17.0-NC; 27% maturity). Most common adverse events (AEs; any grade): rash (44.9%), diarrhoea (30.8%); CTC (Common Toxicity Criteria) grade 3/4 AEs: 15%; SAEs: 19%. Baseline plasma 1 samples were available in 803 patients (784 known mutation status; 82 positive; mutation frequency 10%). Plasma 1 EGFR mutation test sensitivity: 65.7% (95% CI 55.8-74.7).

Conclusion: First-line gefitinib was effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC. Plasma samples could be considered for mutation analysis if tumour tissue is unavailable.

Figures

Figure 1
Figure 1
Patient disposition flow diagram. aAll screened patients. Used to calculate the correlation between clinical characteristics and tumour EGFR mutation status and the comparison of EGFR mutation status between tumour DNA and plasma-derived circulating free DNA. bOne patient of EGFR mutation-positive-ineligible status was treated in error and included in the evaluable-for-safety population. A total of 107 patients therefore started study treatment. cFull analysis set population. Used to summarise efficacy data, and for the comparison of EGFR mutation status in plasma and tumour samples. dNumber of patients with EGFR mutation-positive tumours (n=118) used as the denominator for the percentage calculation. eNumber of patients started on treatment (n=107) used as the denominator for the percentage calculation. Abbreviation: EGFR=epidermal growth factor receptor.
Figure 2
Figure 2
Kaplan–Meier curves for (A) PFS and (B) OS (FAS population). Patients without a PFS event at the time of the primary analysis were censored at the date of their last objective tumour assessment. Abbreviations: CI=confidence interval; NC=not calculable; OS=overall survival; PFS=progression-free survival.

Similar articles

See all similar articles

Cited by 105 articles

See all "Cited by" articles

References

    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. - PubMed
    1. European Medicines Agency 2009. European Public Assessment Report Iressa Summary of Product Characteristics. Available at http://www.ema.europa.eu/ Accessed 13 August 2013.
    1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237–2246. - PubMed
    1. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol. 2012;7:115–121. - PubMed
    1. Greenwood M. The natural duration of cancer. Reports on public health and medical subjects. Her Majesty's Stationery Office. 1926;33:1–26.

Publication types

MeSH terms

Associated data

Feedback